VET3-T12 is under clinical development by KaliVir Immunotherapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs for Sarcomas have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VET3-T12’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VET3-T12 overview
VET3-T12 is under development for the treatment of solid tumors which include breast carcinoma, bladder carcinoma, cervical squamous carcinoma, colorectal carcinoma, esophageal carcinoma, head and neck squamous carcinoma, renal cell carcinoma, ovarian carcinoma, sarcoma, thymoma, and uterine carcinoma. It is administered through intratumor or by intravenous route. The therapeutic candidate comprises genetically modified Vaccinia virus. It is being developed based on Vaccinia Enhanced Template (VET) platform. It acts by targeting transforming growth factor beta (TGF-B), C-X-C Chemokine Receptor Type 3 and IL-12.
KaliVir Immunotherapeutics overview
Kalivir Immunotherapeutics is a biotechnology company that develops, multi-mechanistic oncolytic viral immunotherapies for cancer. It is investigating VET3-TGI, a potent combination of TGF-B inhibition and IL-12 expression derived from the VET, designed to target and kill tumor cells while stimulating anti-cancer immunity. Kalivir Immunotherapeutics utilizes VET, a platform that utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to
For a complete picture of VET3-T12’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
